These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
42. The cost and effectiveness of adherence-improving interventions for antihypertensive and lipid-lowering drugs*. Chapman RH; Ferrufino CP; Kowal SL; Classi P; Roberts CS Int J Clin Pract; 2010 Jan; 64(2):169-81. PubMed ID: 20089007 [TBL] [Abstract][Full Text] [Related]
43. Lipid Lowering Is Beneficial for Secondary Prevention but Not Primary Prevention in Patients 75 Years and Older. Ebell MH Am Fam Physician; 2021 Jun; 103(11):695-696. PubMed ID: 34060787 [No Abstract] [Full Text] [Related]
44. Landmark lipid-lowering trials in the primary prevention of cardiovascular disease. Chrispin J; Martin SS; Hasan RK; Joshi PH; Minder CM; McEvoy JW; Kohli P; Johnson AE; Wang L; Blaha MJ; Blumenthal RS Clin Cardiol; 2013 Sep; 36(9):516-23. PubMed ID: 23722477 [TBL] [Abstract][Full Text] [Related]
45. Fixed drug combination in hypertension and hyperlipidaemia in the developing world. Seedat YK Cardiovasc J Afr; 2008; 19(3):124-6. PubMed ID: 18568170 [No Abstract] [Full Text] [Related]
46. Pharmacoeconomics of lipid-lowering drugs. Smith DG Curr Atheroscler Rep; 2003 Jan; 5(1):67-72. PubMed ID: 12562545 [TBL] [Abstract][Full Text] [Related]
49. The Effects of Different Aspirin Dosing Frequencies and the Timing of Aspirin Intake in Primary and Secondary Prevention of Cardiovascular Disease: A Systematic Review. Bem D; Lordkipanidzé M; Hodgkinson J; Stevens S; Bayliss S; Moore D; Fitzmaurice D; Dretzke J Clin Pharmacol Ther; 2016 Nov; 100(5):500-512. PubMed ID: 27449968 [TBL] [Abstract][Full Text] [Related]
50. Understanding treatment-subgroup effect in primary and secondary prevention of cardiovascular disease: An exploration using meta-analyses of individual patient data. Torres Roldan VD; Ponce OJ; Urtecho M; Torres GF; Belluzzo T; Montori V; Liu C; Barrera F; Diaz A; Prokop L; Guyatt G; Montori VM J Clin Epidemiol; 2021 Nov; 139():160-166. PubMed ID: 34400257 [TBL] [Abstract][Full Text] [Related]
51. Have we reached the bottom of the bottomless pit- lessons from the recent lipid-lowering trials? Bansal M; Agarwala R Indian Heart J; 2018; 70(3):331-334. PubMed ID: 29961445 [No Abstract] [Full Text] [Related]
52. A systematic literature review of cardiovascular event utilities. Smith DW; Davies EW; Wissinger E; Huelin R; Matza LS; Chung K Expert Rev Pharmacoecon Outcomes Res; 2013 Dec; 13(6):767-90. PubMed ID: 24175732 [TBL] [Abstract][Full Text] [Related]
54. Why published studies of the cost-effectiveness of PCSK-9 inhibitors yielded such markedly different results. Toth PP; Stevens W; Chou JW J Med Econ; 2017 Jul; 20(7):749-751. PubMed ID: 28471246 [No Abstract] [Full Text] [Related]
56. Primordial and primary prevention programs for cardiovascular diseases: from risk assessment through risk communication to risk reduction. A review of the literature. Lancarotte I; Nobre MR Clinics (Sao Paulo); 2016 Nov; 71(11):667-678. PubMed ID: 27982169 [TBL] [Abstract][Full Text] [Related]
57. New Male Users of Lipid-Lowering Drugs for Primary Prevention of Cardiovascular Disease: The Impact of Treatment Persistence on Morbimortality. A Longitudinal Study. Aguilar-Palacio I; Rabanaque MJ; Maldonado L; Chaure A; Abad-Díez JM; León-Latre M; Casasnovas JA; Malo S Int J Environ Res Public Health; 2020 Oct; 17(20):. PubMed ID: 33092211 [TBL] [Abstract][Full Text] [Related]
58. UK review finds statins are cost effective in secondary prevention. Kmietowicz Z BMJ; 1999 Nov; 319(7222):1390. PubMed ID: 10574845 [No Abstract] [Full Text] [Related]